---
schema_version: "secwatch.filing_event.v1"
accession: "0001171520-22-000183"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:48:52.902153+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro reports Q4 revenue $4.3M (+15%) and record 2021 revenue $16.3M (+27%)

## Summary
- Q4 2021 revenue $4.3M (+15% YoY); full-year revenue $16.3M (+27% YoY), seventh consecutive year of growth.
- Biologics & drug delivery revenue $6.8M in 2021 (+31% YoY); supported 929 cases despite COVID.
- Cash and equivalents $54.1M at year-end, up from $20.1M, aided by Feb 2021 public offering raising ~$46.8M net.
- Operating expenses increased to $24.7M (2021) from $15.3M (2020) due to headcount and R&D investments.
- 2022 revenue guidance reaffirmed at $20-22M; progress on pillars including FDA clearance for Array and BCI collab.

## SEC filing metadata
- accession: 0001171520-22-000183
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000183/0001171520-22-000183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000117152022000183/eps10120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171520-22-000183
- JSON: https://secwatch.observer/filing/0001171520-22-000183.json
- Plain text: https://secwatch.observer/filing/0001171520-22-000183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.